To provide services in support of nibib covid-19 radx projects for technical assessments and project management
Ended Purchase Order Awarded Last action
- Contract number
- 75N92021P00061
- Awardee
-
Biocomx UEI FHLJUBQ8YAL7
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,988,775
Award facts
- Opportunity
-
- 75N92021Q0053 Solicitation number
- Biomedical Device Commercialization Entrepreneurial Training Support (COVID) Award Notice · Posted Feb 2, 2021
- Contract value 40% obligated
- $14,864,524.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- Set-aside
- No set-aside
- Competition
- 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$7,225 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $3,434,750 | |
| Exercise an Option | $5,441,000 | |
| Original award | $5,996,000 |
About this award
The National Heart, Lung and Blood Institute awarded Biocomx a $14.86 million firm fixed-price purchase order on January 28, 2021, to provide technical assessments and project management services in support of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) COVID-19 RADx initiative. The contract, which was completed by January 31, 2022, supports efforts to accelerate the development and implementation of rapid, innovative diagnostics for COVID-19. The award includes FAR Deviation Clause 52.223-99, which implements Executive Order 14042 requiring adequate COVID-19 safety protocols for federal contractors. The work was performed in Bethesda, Maryland, and no set-aside designations were utilized for this contract award.
Biocomx brings relevant experience in providing biomedical training, technology assessments, and project management services to the federal government. The company specializes in supporting early-stage biomedical project teams in commercializing their innovations through its BiocomxC3i Program, and has received substantial prior funding from the NIH to deliver similar technical assessment and project management services for the RADx initiative. This contract represents a continuation of Biocomx's work supporting the government's rapid diagnostics development efforts during the COVID-19 pandemic.
Quick answers
Who was awarded contract 75N92021P00061?
75N92021P00061 was awarded to Biocomx by National Heart Lung and Blood Institute (National Institutes of Health) on January 28, 2021.
How much is contract 75N92021P00061 worth?
The government has obligated $5,988,775 on 75N92021P00061. Its current value, with exercised options, is $14,864,525.
Was contract 75N92021P00061 competed?
The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award